life science companies that transform the lives of patients worldwide
Improving patients lives
(Nasdaq: AUPH, TSX: AUP)
life science companies that transform the lives of patients worldwide
Acquired by UCB
life science companies that transform the lives of patients worldwide
Building Better Biologics
(NYSE: ZYME)
Acquired by Gilead Sciences
$11.2B
life science companies that transform the lives of patients worldwide
life science companies that transform the lives of patients worldwide
The immune system preserved
(Nasdaq: GTHX)
ICIZED.
Acquired by Stryker
$1.65B
life science companies that transform the lives of patients worldwide
Severe Asthma
FORMED.
Acquired by Cephalon
$550 million
life science companies that transform the lives of patients worldwide
Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
Trending
Lumira Ventures Appoints Special Advisors and Venture Partner
November 18, 2020
Veteran Pharmaceutical Industry Executives Will Advise Portfolio Companies and Investment Team TORONTO, November 18, 2020 - Lumira Ventures, a leading North American healthcare venture capital... Learn More
“Oh, the Places You’ll Go”: A look back at the Canadian healthcare innovation industry and what lies ahead (Part 2)
November 6, 2020
The Takeaway is a periodic blog by Lumira Ventures that covers themes and trends within the fast-growing Canadian healthcare innovation ecosystem. Please note that the views and opinions expressed... Learn More
enGene Receives Funding Through Cystic Fibrosis Foundation’s Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis
October 29, 2020
OSTON and MONTRÉAL, Oct. 29, 2020 /PRNewswire/ -enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues... Learn More
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
August 27, 2020
Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis August 24, 2020 06:59 AM Eastern Daylight Time NEW YORK... Learn More
Team Lumira
Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Philanthropy
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
Contact Us
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
Toronto
141 Adelaide Street
Suite 770
Toronto, ON
Canada, M5H 3L5
416.213.4223
Montreal
Espace CDPQ
3, Place Ville Marie
Bureau 12350, Niveau L
Montreal, QC
Canada, H3B 0E7
514.844.6927
Vancouver
1021 West Hastings Street,
9th floor
Vancouver, BC
Canada, V6E 0C3
604.558.5156
Boston
303 Wyman Street
Suite 300
Waltham, MA,
USA, 02451-1208
781.530.3868